FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes new pharmaceutical compositions containing agonists of adenosine receptors, in particular, agonists binding with adenosine receptor. Indicated compositions are used for induction of producing or secretion of G-CSF in body, prophylaxis or treatment of adverse toxic effect of drug or for treatment of leukopenia, in particular, caused by medicinal agents and for inhibition of anomalous growth and proliferation of cells.
EFFECT: valuable medicinal properties of compositions, expanding assortment of agents of claimed designation.
36 cl, 20 dwg, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | 2018 |
|
RU2791168C1 |
| THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | 2020 |
|
RU2810114C2 |
| THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | 2018 |
|
RU2790011C2 |
| BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | 2018 |
|
RU2781429C2 |
| SUBSTITUTED ARYLPIPERIDINYLALKYNYL ADENOSINES AS AR AGONISTS | 2007 |
|
RU2442789C2 |
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| AGONISTS OF ADENOSINE A3-RECEPTORS | 2002 |
|
RU2298557C2 |
| COMPOUNDS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND PAIN | 2014 |
|
RU2695358C2 |
| ISOTOPE-LABELED PRODUCTION QUINOLINES, ACTING AS LIGANDS OF ADENOSINE RECEPTOR A | 2005 |
|
RU2379290C2 |
| METHOD OF PREVENTION AND TREATMENT OF LIVER DISEASE WITH APPLICATION OF RECEPTOR A ANTAGONISTS | 2007 |
|
RU2457842C2 |
